Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Velmanase alfa - Chiesi Farmaceutici

Drug Profile

Velmanase alfa - Chiesi Farmaceutici

Alternative Names: ALPHA-MAN project; Lamazym; Lamzede; Recombinant lysosomal alpha-D-mannosidase; Recombinant lysosomal alpha-mannosidase; rhLAMAN; velmanase alfa-tycv

Latest Information Update: 01 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymenex A/S
  • Developer Chiesi Farmaceutici; Zymenex A/S
  • Class Mannosidases; Recombinant proteins
  • Mechanism of Action Alpha-mannosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha-Mannosidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alpha-Mannosidosis

Most Recent Events

  • 24 Feb 2023 US FDA label for velmanase alfa has black box warning for hypersensitivity reactions including anaphylaxis for LAMZEDE
  • 16 Feb 2023 Registered for Alpha-Mannosidosis (In adolescents, In children, In adults) in USA (IV)
  • 16 Feb 2023 Chiesi Farmaceutici announces intention to launch Velmanase alfa for Alpha-Mannosidosis in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top